← Vanda Pharmaceuticals Inc. VNDA
Market Price
$5.22
Market Cap
$301.88M
P/E Ratio
N/A
Revenue (FY 2025)
↑8.7% YoY
$216.10M
3-Yr CAGR: -5.3%
Net Income
↓-1,066.5% YoY
-$220.47M
Net Margin: -102.0%
Free Cash Flow
↓-579.8% YoY
-$110.44M
FCF Yield: -36.58%
EPS (Diluted)
↓-1,033.3% YoY
$-3.74
Basic: $-3.74
Return on Equity
Efficiency
-67.4%
ROA: -817.0%
📊 Multi-Year Historical Performance & Trends
Financial Performance History
Revenue, Net Income & Free Cash Flow
Margins Trend (%)
Gross, Operating & Net Margins
Balance Sheet Strength
Cash, Debt & Equity
Cash Flow Generation
Operating Cash Flow vs CapEx vs FCF
📈 Year-over-Year (YoY) Growth History (VNDA)
All monetary values in millions ($M)| Fiscal Year | Revenue | Revenue YoY | Gross Profit | Net Income | Net Inc YoY | Diluted EPS | EPS YoY | Op. Cash Flow | Free Cash Flow | FCF YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| FY 2016 | $146.0M | — | $81.2M | $-18.0M | — | $-0.41 | — | $-8.1M | $-9.5M | — |
| FY 2017 | $165.1M | +13.1% | $106.9M | $-15.6M | +13.6% | $-0.35 | +14.6% | $-2.0M | $-3.6M | +61.7% |
| FY 2018 | $193.1M | +17.0% | $127.5M | $25.2M | +261.9% | $0.48 | +237.1% | $30.0M | $29.6M | +912.1% |
| FY 2019 | $227.2M | +17.6% | $152.5M | $115.6M | +358.4% | $2.11 | +339.6% | $45.9M | $44.9M | +51.7% |
| FY 2020 | $248.2M | +9.2% | $167.7M | $23.3M | -79.8% | $0.42 | -80.1% | $51.8M | $50.0M | +11.2% |
| FY 2021 | $268.7M | +8.3% | $166.2M | $33.2M | +42.1% | $0.58 | +38.1% | $64.2M | $63.7M | +27.4% |
| FY 2022 | $254.4M | -5.3% | $142.8M | $6.3M | -81.1% | $0.11 | -81.0% | $32.0M | $31.3M | -50.8% |
| FY 2023 | $192.6M | -24.3% | $126.8M | $2.5M | -60.0% | $0.04 | -63.6% | $12.8M | $12.4M | -60.3% |
| FY 2024 | $198.8M | +3.2% | $105.8M | $-18.9M | -853.3% | $-0.33 | -925.0% | $-15.8M | $-16.2M | -230.8% |
| FY 2025 | $216.1M | +8.7% | $86.8M | $-220.5M | -1,066.5% | $-3.74 | -1,033.3% | $-109.4M | $-110.4M | -579.8% |
Valuation
Market Price
$5.22
Market Cap
$301.88M
Enterprise Value
N/A
P/E Ratio
N/A
P/B Ratio
0.96
FCF Yield
-36.58%
Dividend Yield
N/A
Shares Outstanding
Profitability & Margins
Gross Margin
40.16%
Operating Margin
-69.95%
Net Margin
-102.02%
Return on Equity (ROE)
-67.38%
Return on Assets (ROA)
-817.02%
Asset Turnover
8.01x
Revenue 3-Yr CAGR
-5.29%
Financial Health & Liquidity
Current Ratio
0.19
Cash Ratio
0.58
Debt / Equity
N/A
Debt / Assets
N/A
Cash & Equivalents
$84.85M
Total Debt
N/A
Book Value / Share
$5.44
Cash Flow Efficiency
Operating Cash Flow
-$109.44M
Capital Expenditures (CapEx)
$998.00K
Free Cash Flow
-$110.44M
OCF / Revenue
-50.64%
FCF / Revenue
-51.10%
FCF 3-Yr CAGR
N/A
Per Share Metrics
EPS (Diluted)
$-3.74
EPS (Basic)
$-3.74
Dividends / Share
N/A
Book Value / Share
$5.44
EPS YoY Growth
-1,033.33%
Balance Sheet (FY 2025)
Total Assets
$26.98M
Total Liabilities
$145.16M
Stockholders' Equity
$327.19M
Current Assets
$26.98M
Current Liabilities
$145.16M